AstraZeneca Pharma India Limited has submitted a compliance certificate for the quarter ended June 30, 2026. The certificate, issued by Integrated Registry Management Services Private Limited, confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This demonstrates the company’s commitment to maintaining robust practices in share dematerialization and corporate governance, ensuring compliance with regulatory requirements.
Compliance Certificate Submitted
AstraZeneca Pharma India Limited has officially submitted a compliance certificate to the stock exchanges, confirming adherence to the requirements of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certification pertains to the financial quarter that concluded on June 30, 2026.
Key Details of the Certificate
The certificate was issued on July 27, 2026, by Integrated Registry Management Services Private Limited, the appointed Registrar and Transfer Agents (RTA) for the company. It specifically addresses the company’s compliance with regulations concerning the dematerialization of securities. The RTA has confirmed that AstraZeneca Pharma India Limited has fulfilled its obligations within the stipulated timeframe of 15 days from the receipt of certificates for dematerialization.
Dematerialization Process Confirmation
The RTA’s confirmation includes several key actions undertaken to ensure compliance:
- The securities that were dematerialized are listed on the stock exchange(s) where the earlier issued securities were traded.
- Any mutilated and canceled share certificates forwarded by depository participants have been duly processed.
- The name of the depository has been substituted as the registered owner in the company’s records.
This submission underscores AstraZeneca Pharma India Limited’s commitment to transparent and compliant corporate practices, particularly in managing its shareholder and securities-related operations in accordance with SEBI guidelines.
Company Information
AstraZeneca Pharma India Limited continues to operate with a focus on maintaining regulatory compliance and efficient corporate governance. The company’s corporate and registered office is located in Bangalore, India.
Source: BSE
